EpiEndo completes a €9m convertible bond issue to drive further development of glasmacinal

• €9m funding via convertible bond issuance
  • €5m new funding from both new and existing investors
  • €4m of existing convertibles rolled into the new bond
• Proceeds to fund further development and manufacturing work for lead asset glasmacinal, ahead of future Phase 2b trial in COPD patients
• Glasmacinal is the first candidate in a new class of orally available macrolide drugs with reduced antimicrobial resistance, in clinical development

REYKJAVIK, ICELAND – 7 January 2026 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases, has raised €5m of new funding from new and existing investors via a €9m convertible bond issuance, which also included a rollover of an outstanding convertible bond issued in 2023.

The funding will enable further development of EpiEndo’s lead asset glasmacinal (EP395). It is the first in a new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, and shows promise as a therapeutic for chronic respiratory diseases, such as COPD.

The encouraging data from EpiEndo’s Phase 2a trial of glasmacinal in COPD patients demonstrated that it was well tolerated and reduced neutrophilic inflammation as well as having no detectable impact on the lung microbiome, supporting its claim of negligible anti-microbial activity.

The Company aims to continue development of glasmacinal in a larger Phase 2b trial. In preparation, key chemical, manufacturing and control (CMC) work is required which this bond issuance will finance.

The convertible bond brings new private and institutional investors to EpiEndo.

Maria Bech, CEO of EpiEndo Pharmaceuticals commented:

“This funding enables the continued development of glasmacinal, as we deliver the key CMC preparation work needed ahead of a larger future Phase 2 exacerbation reduction trial in COPD patients.

“With the level of understanding we now have about glasmacinal’s anti-inflammatory and host-defence enhancing properties, we believe that it has real potential as a chronic treatment for patients with COPD who continue to experience exacerbations, despite receiving the current standard of care.”

Stefan Petursson, CFO of EpiEndo Pharmaceuticals added:

“We are pleased to welcome new investors to EpiEndo and value their support for our unique approach to chronic respiratory disease, as we continue to drive our first-in class asset through the clinic.”

-ENDS-

Contact:

EpiEndo Pharmaceuticals:
Maria Bech, CEO
+354 454 0090­­­

Vigo Consulting (media relations):
Rozi Morris
+44 20 7390 0230
epiendo@vigoconsulting.com

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders.

EpiEndo’s new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as ‘Barriolides™’, show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD).

Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution.​ Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD.

According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.